Latest Information Update: 03 Jul 2002
At a glance
- Originator Aventis
- Developer Nonindustrial source
- Mechanism of Action Glycine NMDA-associated antagonists; NMDA receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- No development reported Neuroprotection
Most Recent Events
- 19 Jun 1997 Preclinical development for Neuroprotection in USA (Unknown route)